Get the Stockscreener App
2.3399
4.12%
-0.0901
Spero Therapeutics Inc stock is traded at $2.3399, with a volume of 156.18K.
It is down -4.12% in the last 24 hours and up +13.66% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.43
Open:
$2.44
24h Volume:
156.18K
Relative Volume:
0.23
Market Cap:
$131.57M
Revenue:
$76.19M
Net Income/Loss:
$-1.61M
P/E Ratio:
233.99
EPS:
0.01
Net Cash Flow:
$28.98M
1W Performance:
+1.75%
1M Performance:
+13.66%
6M Performance:
+260.12%
1Y Performance:
+97.46%
1-Day Range:
$2.33
$2.465
1-Week Range:
$2.27
$2.475
52-Week Range:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.338 | 136.75M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.97 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.67 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.67 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.64 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.94 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
How Spero Therapeutics Inc. stock compares to industry benchmarksQuarterly Portfolio Summary & AI Based Buy and Sell Signals - newser.com
How Spero Therapeutics Inc. stock reacts to inflationary pressuresPortfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
Using flow based indicators on Spero Therapeutics Inc.Quarterly Growth Report & AI Driven Stock Reports - newser.com
What earnings margins imply for Spero Therapeutics Inc. (2HA) stockQuarterly Profit Summary & High Win Rate Trade Tips - newser.com
What analysts say about Spero Therapeutics Inc stockSupport and Resistance Levels & Free Unlock Hidden Market Opportunities - earlytimes.in
What analysts say about China Pharma Holdings Inc stockHealthcare Stock Analysis & Rapid Profit Growth - earlytimes.in
Will Spero Therapeutics Inc. stock keep outperforming rivalsPortfolio Update Report & Risk Adjusted Swing Trade Ideas - newser.com
Will Spero Therapeutics Inc. stock sustain high P E ratiosEarnings Recap Report & Daily Profit Maximizing Tips - newser.com
Will breakout in Spero Therapeutics Inc. lead to full recoveryTrade Risk Summary & Step-by-Step Swing Trade Plans - newser.com
What recovery options are there for Spero Therapeutics Inc.Weekly Loss Report & Free Real-Time Market Sentiment Alerts - newser.com
Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Down 42.5% in October - MarketBeat
Will Spero Therapeutics Inc. benefit from macro trendsEarnings Risk Report & Long-Term Investment Growth Plans - newser.com
How sustainable is Spero Therapeutics Inc. stock dividend payoutMarket Activity Summary & Expert Verified Stock Movement Alerts - newser.com
What does recent volatility data suggest for Spero Therapeutics Inc.Quarterly Market Summary & Stepwise Swing Trade Plans - newser.com
Is Spero Therapeutics Inc. (2HA) stock undervalued historicallyTrade Volume Report & Free Technical Confirmation Trade Alerts - newser.com
Published on: 2025-11-01 09:23:51 - newser.com
Will Spero Therapeutics Inc. stock recover after recent drop2025 Market Outlook & Fast Exit and Entry Strategy Plans - newser.com
Spero Therapeutics Inc. stock daily chart insights2025 Trading Volume Trends & High Accuracy Swing Trade Signals - newser.com
Will Spero Therapeutics Inc. stock pay special dividendsMarket Activity Report & Daily Profit Focused Stock Screening - newser.com
Published on: 2025-10-31 10:27:16 - newser.com
Why Spero Therapeutics Inc. (2HA) stock is trending on social mediaWeekly Earnings Recap & Verified Momentum Stock Alerts - newser.com
How to monitor Spero Therapeutics Inc. with trend dashboards2025 Trading Volume Trends & Daily Stock Trend Watchlist - newser.com
Will Spero Therapeutics Inc. stock remain a Wall Street favoriteMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
Why Spero Therapeutics Inc. (2HA) stock is listed among top recommendationsWeekly Trade Summary & Accurate Entry and Exit Point Alerts - newser.com
Published on: 2025-10-30 05:46:40 - newser.com
What MACD signals say about Spero Therapeutics Inc.Market Trend Report & Weekly Stock Breakout Alerts - newser.com
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):